$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2018 Q2 Form 10-Q Financial Statement

#000128581918000006 Filed on May 10, 2018

Income Statement

Concept	2018 Q2	2018 Q1	2017 Q1
Revenue	$1.655M	$1.588M	$12.26M
YoY Change	-90.35%	-87.04%	65.21%
Cost Of Revenue	$116.0K	$203.0K	$271.0K
YoY Change	-26.11%	-25.09%	-17.13%
Gross Profit	$1.539M	$1.385M	$11.99M
YoY Change	-90.94%	-88.44%	69.01%
Gross Profit Margin	92.99%	87.22%	97.79%
Selling, General & Admin	$12.74M	$10.93M	$12.47M
YoY Change	-19.37%	-12.35%	12.24%
% of Gross Profit	827.81%	789.17%	104.04%
Research & Development	$19.41M	$18.14M	$12.24M
YoY Change	47.77%	48.2%	-20.69%
% of Gross Profit	1261.34%	1309.75%	102.12%
Depreciation & Amortization	$210.0K	$220.0K	$120.0K
YoY Change	90.91%	83.33%	140.0%
% of Gross Profit	13.65%	15.88%	1.0%
Operating Expenses	$32.27M	$29.28M	$24.98M
YoY Change	10.94%	17.19%	-7.03%
Operating Profit	-$30.62M	-$27.69M	-$12.73M
YoY Change	156.45%	117.6%	-34.58%
Interest Expense	$3.676M	$2.825M	$2.663M
YoY Change	35.0%	6.08%	93.67%
% of Operating Profit
Other Income/Expense, Net	$597.0K	$460.0K	$299.0K
YoY Change	97.03%	53.85%	3.82%
Pretax Income	-$33.70M	-$30.05M	-$15.09M
YoY Change	134.68%	99.14%	-26.53%
Income Tax
% Of Pretax Income
Net Earnings	-$33.70M	-$30.05M	-$15.09M
YoY Change	134.67%	99.18%	-26.53%
Net Earnings / Revenue	-2036.01%	-1892.57%	-123.11%
Basic Earnings Per Share
Diluted Earnings Per Share	-$696.6K	-$622.4K	-$344.3K
COMMON SHARES
Basic Shares Outstanding	48.29M shares	48.29M shares	43.82M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q2	2018 Q1	2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$88.40M	$72.80M	$33.70M
YoY Change	197.64%	116.02%	155.3%
Cash & Equivalents	$2.883M	$1.189M	$1.282M
Short-Term Investments	$85.50M	$71.60M	$32.40M
Other Short-Term Assets	$6.300M	$5.400M	$3.300M
YoY Change	85.29%	63.64%	32.0%
Inventory	$235.0K	$247.0K	$960.0K
Prepaid Expenses	$6.336M	$5.441M	$3.260M
Receivables	$1.500M	$0.00	$13.50M
Other Receivables	$29.00K	$133.0K	$0.00
Total Short-Term Assets	$96.50M	$78.68M	$51.35M
YoY Change	81.76%	53.22%	111.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.436M	$2.081M	$1.215M
YoY Change	70.83%	71.28%	35.3%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$7.400M	$8.300M	$5.800M
YoY Change	27.59%	43.1%	7845.21%
Total Long-Term Assets	$9.845M	$10.35M	$7.050M
YoY Change	35.59%	46.82%	-39.48%
TOTAL ASSETS
Total Short-Term Assets	$96.50M	$78.68M	$51.35M
Total Long-Term Assets	$9.845M	$10.35M	$7.050M
Total Assets	$106.3M	$89.04M	$58.40M
YoY Change	76.21%	52.45%	62.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.85M	$10.18M	$2.409M
YoY Change	360.73%	322.71%	-54.82%
Accrued Expenses	$11.98M	$13.93M	$14.34M
YoY Change	-44.63%	-2.8%	18.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$608.0K	$513.0K	$228.0K
YoY Change	143.2%	125.0%	230.43%
Total Short-Term Liabilities	$24.44M	$24.63M	$16.97M
YoY Change	-1.26%	45.11%	-3.13%
LONG-TERM LIABILITIES
Long-Term Debt	$129.8M	$85.04M	$80.50M
YoY Change	59.18%	5.63%	61.09%
Other Long-Term Liabilities	$8.500M	$8.600M	$9.000M
YoY Change	-4.49%	-4.44%	-2.17%
Total Long-Term Liabilities	$129.8M	$85.04M	$80.50M
YoY Change	59.18%	5.63%	61.09%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.44M	$24.63M	$16.97M
Total Long-Term Liabilities	$129.8M	$85.04M	$80.50M
Total Liabilities	$154.2M	$109.7M	$97.48M
YoY Change	45.1%	12.51%	44.42%
SHAREHOLDERS EQUITY
Retained Earnings	-$587.1M	-$553.4M	-$485.0M
YoY Change	17.58%	14.11%	14.47%
Common Stock	$485.0K	$483.0K	$439.0K
YoY Change	9.23%	10.02%	12.28%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$56.30M	-$29.22M	-$48.11M
YoY Change
Total Liabilities & Shareholders Equity	$106.3M	$89.04M	$58.40M
YoY Change	76.21%	52.45%	62.36%

Cashflow Statement

Concept	2018 Q2	2018 Q1	2017 Q1
OPERATING ACTIVITIES
Net Income	-$33.70M	-$30.05M	-$15.09M
YoY Change	134.67%	99.18%	-26.53%
Depreciation, Depletion And Amortization	$210.0K	$220.0K	$120.0K
YoY Change	90.91%	83.33%	140.0%
Cash From Operating Activities	-$30.91M	-$11.30M	-$12.70M
YoY Change	278.8%	-11.07%	-23.61%
INVESTING ACTIVITIES
Capital Expenditures	-$210.0K	$183.0K	$72.00K
YoY Change	-16.0%	154.17%
Acquisitions
YoY Change
Other Investing Activities	-$13.90M	$8.730M	$10.74M
YoY Change	-328.24%	-18.72%	-26.59%
Cash From Investing Activities	-$14.10M	$8.547M	$10.66M
YoY Change	-341.03%	-19.85%	-27.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$687.0K	$1.147M
YoY Change		-40.1%	15193.33%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	46.71M	$544.0K	$1.096M
YoY Change	959.18%	-50.36%	-31.88%
NET CHANGE
Cash From Operating Activities	-30.91M	-$11.30M	-$12.70M
Cash From Investing Activities	-14.10M	$8.547M	$10.66M
Cash From Financing Activities	46.71M	$544.0K	$1.096M
Net Change In Cash	1.700M	-$2.205M	-$942.0K
YoY Change	-19.05%	134.08%	143.41%
FREE CASH FLOW
Cash From Operating Activities	-$30.91M	-$11.30M	-$12.70M
Capital Expenditures	-$210.0K	$183.0K	$72.00K
Free Cash Flow	-$30.70M	-$11.48M	-$12.77M
YoY Change	288.12%	-10.14%	-23.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2018Q1	dei	Amendment Flag AmendmentFlag	false
CY2018Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2018Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018Q1	dei	Document Period End Date DocumentPeriodEndDate	2018-03-31
CY2018Q1	dei	Document Type DocumentType	10-Q
CY2018Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2018Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	48292608	shares
CY2018Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2018Q1	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
CY2018Q1	dei	Trading Symbol TradingSymbol	OMER
CY2017Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1026000	USD
CY2018Q1	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1118000	USD
CY2017Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	4251000	USD
CY2018Q1	omer	Accrued Contract Research Costs AccruedContractResearchCosts	4763000	USD
CY2017Q4	omer	Advanced Payments Noncurrent AdvancedPaymentsNoncurrent	0	USD
CY2018Q1	omer	Advanced Payments Noncurrent AdvancedPaymentsNoncurrent	2435000	USD
CY2017Q4	omer	Hospital Return Liability Current HospitalReturnLiabilityCurrent	2350000	USD
CY2018Q1	omer	Hospital Return Liability Current HospitalReturnLiabilityCurrent	0	USD
CY2018Q1	omer	Long Term Purchase Commitment Termination Fee LongTermPurchaseCommitmentTerminationFee	15300000	USD
CY2017Q1	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	805000	USD
CY2018Q1	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	838000	USD
CY2018Q1	omer	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumber	2544474	shares
CY2017Q1	omer	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	117898	shares
CY2018Q1	omer	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	75616	shares
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6691000	USD
CY2018Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	10183000	USD
CY2017Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	17079000	USD
CY2018Q1	us-gaap	Accounts Receivable Net AccountsReceivableNet	49000	USD
CY2017Q4	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	6561000	USD
CY2018Q1	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	1825000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	19126000	USD
CY2018Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13934000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1758000	USD
CY2018Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1494000	USD
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	520072000	USD
CY2018Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	523724000	USD
CY2017Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11024664	shares
CY2018Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9741054	shares
CY2017Q4	us-gaap	Assets Assets	116328000	USD
CY2018Q1	us-gaap	Assets Assets	89035000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	108372000	USD
CY2018Q1	us-gaap	Assets Current AssetsCurrent	78684000	USD
CY2017Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	80355000	USD
CY2018Q1	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	71625000	USD
CY2017Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	1300000	USD
CY2018Q1	us-gaap	Capital Lease Obligations CapitalLeaseObligations	1180000	USD
CY2017Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	70000	USD
CY2018Q1	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2017Q4	us-gaap	Cash Cash	3400000	USD
CY2018Q1	us-gaap	Cash Cash	1200000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2224000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1282000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3394000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1189000	USD
CY2017Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-942000	USD
CY2018Q1	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2205000	USD
CY2018Q1	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	72800000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2018Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2018Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48211226	shares
CY2018Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	48286842	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48211226	shares
CY2018Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	48286842	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	482000	USD
CY2018Q1	us-gaap	Common Stock Value CommonStockValue	483000	USD
CY2017Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-15089000	USD
CY2018Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-30054000	USD
CY2017Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	271000	USD
CY2018Q1	us-gaap	Cost Of Goods Sold CostOfGoodsSold	203000	USD
CY2017Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	89323000	USD
CY2018Q1	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	90082000	USD
CY2017Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3527000	USD
CY2018Q1	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3400000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1189000	USD
CY2018Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1132000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8718000	USD
CY2018Q1	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8583000	USD
CY2017Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	115000	USD
CY2018Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	223000	USD
CY2017Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2018Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.62
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2178000	USD
CY2018Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3727000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16600000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1002000	USD
CY2018Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1007000	USD
CY2018Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y4M9D
CY2017Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	12471000	USD
CY2018Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10934000	USD
CY2017Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	771000	USD
CY2018Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1835000	USD
CY2017Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-168000	USD
CY2018Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-196000	USD
CY2017Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1494000	USD
CY2018Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	840000	USD
CY2017Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	1444000	USD
CY2018Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-16962000	USD
CY2017Q1	us-gaap	Interest Expense InterestExpense	2663000	USD
CY2018Q1	us-gaap	Interest Expense InterestExpense	2825000	USD
CY2017Q1	us-gaap	Interest Paid InterestPaid	1667000	USD
CY2018Q1	us-gaap	Interest Paid InterestPaid	1739000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	443000	USD
CY2018Q1	us-gaap	Inventory Net InventoryNet	247000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	116328000	USD
CY2018Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	89035000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26307000	USD
CY2018Q1	us-gaap	Liabilities Current LiabilitiesCurrent	24630000	USD
CY2017Q4	us-gaap	Loans Payable LoansPayable	4192000	USD
CY2018Q1	us-gaap	Loans Payable LoansPayable	4233000	USD
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	490000	USD
CY2018Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	513000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	84117000	USD
CY2018Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	85037000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1096000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	544000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10664000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	8547000	USD
CY2017Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12702000	USD
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-36200000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11296000	USD
CY2018Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11300000	USD
CY2017Q1	us-gaap	Net Income Loss NetIncomeLoss	-15089000	USD
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-53500000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-30100000	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-30054000	USD
CY2017Q4	us-gaap	Notes Payable NotesPayable	83831000	USD
CY2018Q1	us-gaap	Notes Payable NotesPayable	84669000	USD
CY2018Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2017Q1	us-gaap	Operating Expenses OperatingExpenses	24982000	USD
CY2018Q1	us-gaap	Operating Expenses OperatingExpenses	29277000	USD
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-12725000	USD
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-27689000	USD
CY2017Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	299000	USD
CY2018Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	460000	USD
CY2017Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	65000	USD
CY2018Q1	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	133000	USD
CY2017Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	995000	USD
CY2018Q1	us-gaap	Paid In Kind Interest PaidInKindInterest	1086000	USD
CY2017Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	1042000	USD
CY2018Q1	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	270000	USD
CY2017Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	72000	USD
CY2018Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	183000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2018Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2018Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2018Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	7036000	USD
CY2018Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	5441000	USD
CY2017Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1147000	USD
CY2018Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	687000	USD
CY2017Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	11778000	USD
CY2018Q1	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	9000000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2121000	USD
CY2018Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2081000	USD
CY2017Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	17144000	USD
CY2018Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	182000	USD
CY2017Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	51000	USD
CY2018Q1	us-gaap	Repayments Of Debt And Capital Lease Obligations RepaymentsOfDebtAndCapitalLeaseObligations	143000	USD
CY2017Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12240000	USD
CY2018Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18140000	USD
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5835000	USD
CY2018Q1	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5835000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-523368000	USD
CY2018Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-553422000	USD
CY2017Q1	us-gaap	Revenues Revenues		USD
CY2018Q1	us-gaap	Revenues Revenues		USD
CY2017Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	12257000	USD
CY2018Q1	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	1588000	USD
CY2017Q1	us-gaap	Share Based Compensation ShareBasedCompensation	3276000	USD
CY2018Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2966000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3453231	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7095978	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.68
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	21741	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	15.80
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	80550	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	13760000	USD
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9657259	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9640452	shares
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.39
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.42
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	13687000	USD
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9373849	shares
CY2018Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.36
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	9.09
CY2018Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.49
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	13056000	USD
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M21D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M25D
CY2018Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y6M
CY2018Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	75616	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	-2814000	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	-29215000	USD
CY2017	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2018Q1	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2017Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43828572	shares
CY2018Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	48284019	shares
CY2018Q1	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We generally record revenue from product sales when the product is delivered to our wholesalers. Product sales are recorded net of wholesaler distribution fees and estimated chargebacks, rebates and purchase volume discounts. Accruals or allowances are established for these deductions in the same period when revenue is recognized, and actual amounts incurred are offset against the applicable accruals or allowances. We reflect each of these accruals or allowances as either a reduction in the related account receivable or as an accrued liability, depending on how the amount is expected to be settled. </font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Centers for Medicare and Medicaid Services (CMS) granted transitional pass-through reimbursement status for OMIDRIA through December 31, 2017. Pass-through status for OMIDRIA allowed for reimbursement payment to Ambulatory Surgery Centers (ASCs) and hospitals using OMIDRIA in procedures involving patients covered by Medicare Part B. In March 2018, the Consolidated Appropriations Act, 2018 (the Appropriations Act) was signed into law, which among other things extended pass-through reimbursement status for certain drugs, including OMIDRIA, for a two-year period beginning October 1, 2018. For the period January 1, 2018 through September 30, 2018, OMIDRIA is not subject to reimbursement payment for procedures involving patients covered by Medicare Part B.</font></div><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div>
CY2018Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:12px;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:12px;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, stock-based compensation expense and accruals for clinical trials, manufacturing of drug product and clinical drug supply and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div><div style="line-height:120%;padding-bottom:12px;text-align:left;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;"></font></div></div>

Files In Submission

Name	View Source	Status
0001285819-18-000006-index-headers.html	Edgar Link	pending
0001285819-18-000006-index.html	Edgar Link	pending
0001285819-18-000006.txt	Edgar Link	pending
0001285819-18-000006-xbrl.zip	Edgar Link	pending
ex121_20180331.htm	Edgar Link	pending
ex311_20180331.htm	Edgar Link	pending
ex312_20180331.htm	Edgar Link	pending
ex321_20180331.htm	Edgar Link	pending
ex322_20180331.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
omer-20180331.xml	Edgar Link	completed
omer-20180331.xsd	Edgar Link	pending
omer-20180331x10q.htm	Edgar Link	pending
omer-20180331_cal.xml	Edgar Link	unprocessable
omer-20180331_def.xml	Edgar Link	unprocessable
omer-20180331_lab.xml	Edgar Link	unprocessable
omer-20180331_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2018 Q2 Form 10-Q Financial Statement

#000128581918000006 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2018 Q2 Form 10-Q Financial Statement

#000128581918000006 Filed on May 10, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer